ARIAD Pharmaceuticals, Inc. (ARIA)

ARIA AZT PROTECT™ secures critical production applications from attacks and dangerous unintentional ICS updates BOSTON, MA / ACCESS Newswire / August 12, 2025 / ARIA Cybersecurity, a CSPi business (NASDAQ:CSPI) and a leading provider of cybersecurity solutions, announced a new customer deployment of ARIA's flagship solution, AZT PROTECT ™, which works to protect steel plant operations at a mill of one of the largest US steel producers. This large steel producer became concerned that attacks would get through IT defenses into its production OT network and take down critical production systems.

Two Michelin-starred London restaurant launches first U.S. location, blending fine Indian cuisine within a vibrant setting LAS VEGAS , Aug. 6, 2025 /PRNewswire/ -- In a bold move set to redefine the Las Vegas dining scene and welcome a new chapter of culinary excellence, ARIA Resort & Casino will debut the acclaimed Two Michelin-starred restaurant Gymkhana, this fall. Inspired by the private clubs of India – where high society gathers to dine, drink, socialize and play sport – Gymkhana will introduce a new level of sophistication to ARIA's food and beverage portfolio, further cementing the resort's reputation as a premier culinary destination in the heart of the Las Vegas Strip.

ARIA AZT PROTECT(TM) secures 1000s of cell tower sites from both cyber and physical asset threats BOSTON, MASSACHUSETTS / ACCESS Newswire / July 1, 2025 / ARIA Cybersecurity, a CSPi business (NASDAQ:CSPI) and a leading provider of cybersecurity solutions, announced a new contract via its reseller partnership with Oryx Industries to deploy ARIA's flagship solution, AZT PROTECT ™, to protect cell tower visual monitoring systems in South Africa. Oryx Industries is actively promoting AZT PROTECT to a range of customer verticals across South Africa in response to a rise in cyberattacks targeting the country's critical infrastructure.

ARIA AZT PROTECT to stop cyberattacks targeting 1000s of cell tower sites BOSTON, MA / ACCESS Newswire / April 8, 2025 / ARIA Cybersecurity, a CSPi business (NASDAQ:CSPi) and a leading provider of cybersecurity solutions announced a new contract via its new reseller partnership with Oryx to deploy ARIA's flagship solution, AZT PROTECT ™, to protect equipment at one of the largest cell tower owners in South Africa. Oryx Industries is actively promoting AZT PROTECT to a range of customer verticals across South Africa in response to a rise in cyberattacks targeting the country's critical infrastructure.

Strategic Collaboration Brings Cutting-Edge Cybersecurity to Operational Technology Environments LOWELL, MA / ACCESS Newswire / March 5, 2025 / Oryx Industries, a leading provider of trailblazing cybersecurity solutions, has announced a strategic partnership with ARIA Cybersecurity, a CSPi business (NASDAQ:CSPi), integrating the ARIA Zero Trust PROTECT™ (AZT PROTECT™) solution into its award-winning security portfolio. This collaboration brings an AI-driven, critical infrastructure solution to South African businesses and organizations who are looking to protect all Operational Technology (OT) endpoints from both known and unknown cyber threats.

Rexel adopts ARIA AZT PROTECT™ to stop cyberattacks targeting critical industrial infrastructure, completes deployment at first customer site in just one hour LOWELL, MA / ACCESS Newswire / February 26, 2025 / ARIA Cybersecurity, a CSPi business (NASDAQ:CSPi) and a leading provider of cybersecurity solutions announced a new reseller partnership with Rexel USA, an industry leader in supplying industrial equipment throughout the United States. Rexel provides a variety of products to industrial customers across the U.S. and is a premier Rockwell Automation distributor.

UFT to Resell ARIA AZT PROTECT™ to stop cyberattacks targeting Water Treatment and Wastewater facilities throughout North America BOSTON, MA / ACCESSWIRE / December 23, 2024 / ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPi) a leading provider of cybersecurity solutions announced a new reseller partnership with United Flow Technologies (UFT) the industry leader in providing equipment and services to the water treatment industry. UFT provides products and system integration services to water and wastewater treatment facilities across 40 US states.

CED to Resell ARIA AZT PROTECT™ BOSTON, MA / ACCESSWIRE / November 25, 2024 / ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPi) a leading provider of cybersecurity solutions announced a new reseller partnership with CED Industrial Solutions Network an industry-leading provider of Rockwell Automation software and equipment in the US. CED provides industrial products and solutions across 19 US states.

Large growing independent retail energy producer begins to deploy ARIA AZT PROTECT across its footprint of over 30 plants BOSTON, MA / ACCESSWIRE / November 21, 2024 / ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPi) a leading provider of cybersecurity solutions announced a new customer in the energy sector. ARIA's AZT PROTECT™ zero trust solution provides a lock-down approach to protecting critical infrastructure applications from attack, focusing on stopping all forms of zero-day malware, ransomware as well as nation-state-backed attacks on these applications and the operating systems on which they run.

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard dosing regimen used in the pivotal Phase 3 clinical trial Reduction of amyloid plaque and P-tau217 on this modified titration was comparable to patients receiving the standard dosing regimen Lilly intends to submit this data to global regulators for a potential label update for Kisunla (donanemab-azbt) INDIANAPOLIS , Oct. 29, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging abnormalities with edema/effusion (ARIA-E) at the 24-week primary endpoint for people receiving a slightly modified titration of donanemab in adults with early symptomatic Alzheimer's disease (AD).1 Donanemab is approved under the brand name Kisunla™ in the United States, Japan, Great Britain and other countries. These data were presented at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain.

WEST PALM BEACH, Fla. , Oct. 24, 2024 /PRNewswire/ -- Ethema Health Corporation's (OTCPINK: GRST) ("Ethema" "GRST" or the "Company"), wholly owned subsidiary ARIA, received its full license to operate an inpatient detoxication and Residential Level 1 facility on October 21, 2024 from the Department of Children and Family Services for our new facility located at 899 Meadows Avenue, Boca Raton, Florida ("ARIA Boca").

ARIA Cybersecurity asked to update the industry on cybersecurity risk measurement and attack defense strategies BOSTON, MA / ACCESSWIRE / July 26, 2024 / ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPi), has been selected to update the industry on how to measure the cybersecurity risks facing industrial operations-and how to guard against them-at the Rockwell Automation Fair hosted by Rockwell Automation. Taking place November 18th - 21st in Anaheim, California, the event will bring together 10,000 leaders from across the industry to discuss the latest challenges facing industrial automation, including the sharp increase in cybersecurity attacks on critical infrastructure.

ARIA AZT PROTECT Combined with the Forescout Platform Delivers Enhanced OT Critical Application Visibility and Protection LOWELL, MA / ACCESSWIRE / June 27, 2024 / ARIA Cybersecurity Solutions, a CSPi business (NASDAQ:CSPi) a leading provider of cybersecurity solutions,announced a new integration partnership with Forescout Technologies, Inc. Forescout helps customers detect, protect, and respond to the latest risks and threats. With a deep view of asset intelligence captured throughout the Forescout Platform, customers have better visibility of active risks and threats, enabling them to make better risk prioritization and mitigation decisions.

TOKYO and CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Eisai Co., Ltd.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals (NASDAQ:ARIA) (“ARIAD”) today announced it has entered into a definitive agreement to be acquired by Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or a total enterprise value of approximately $5.2 billion, representing a premium of approximately 75 percent over ARIAD’s closing price on January 6, 2017. Under the terms of the agreement, ARIAD stockholders will receive $24.00 in cash for each share of ARIAD common stock they own. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Paris Panayiotopoulos, President and Chief Executive Officer of ARIAD, said, “We are very pleased to combine with Takeda, which will allow us to not only accelerate our mission to discover, develop and deliver precision therapies to patients with rare cancers, but also deliver meaningful value to our shareholders through a substantial cash premium. This exciting transaction is a testament to the hard work and dedication of ARIAD’s talented team of employees. We have tremendous respect for Takeda, and I believe our shared commitment to innovation and research-driven cultures will provide for a smooth transition.” Alexander J. Denner, Ph.D., Chairman of the ARIAD Board of Directors, said: “This transaction is a great outcome for ARIAD shareholders and brings hope to improve the lives of many cancer patients. It has been a pleasure to work with our outstanding management team and, on behalf of the board of directors, I extend our deepest gratitude to everyone at ARIAD for their unrelenting dedication.” Dr. Denner continued, “The transaction also underscores the tremendous value that shareholder activism can create for shareholders, patients and society. While ARIAD’s stock price was collapsing and many investors were abandoning the company, Sarissa Capital saw a company with important drugs and innovation and stepped in to become one of ARIAD’s largest shareholders. However, many things needed to be fixed before the value could be realized. With a new board and management team, ARIAD was able to focus on optimal capital allocation and operational excellence. As a result, the company created meaningful shareholder value and advance the options for those suffering from rare cancers.” “The acquisition of ARIAD is a unique opportunity that will enable us to positively impact the lives of more patients worldwide, advance our strategic priorities and generate attractive returns for our shareholders,” said Christophe Weber, president and chief executive officer of Takeda. “This is a very exciting time for Takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies. Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this transaction to benefit patients, our shareholders and other stakeholders.” Under the terms of the agreement, the acquisition is structured as an all cash tender offer for all of the outstanding shares of ARIAD common stock, followed by a merger in which remaining shares of ARIAD would be converted into the right to receive the same $24.00 cash per share price paid in the tender offer. The transaction is subject to the tender of a majority of ARIAD common stock on a fully diluted basis as well as other customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the antitrust laws of applicable foreign jurisdictions. The transaction is expected to close by the end of February 2017. Takeda Pharmaceuticals U.S.A., a wholly owned subsidiary of Takeda, has established Kiku Merger Co., Inc. to effect the transaction. JPMorgan, Goldman, Sachs & Co. and Lazard acted as financial advisors to ARIAD Pharmaceuticals and Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as the Company’s legal advisor. Cleary Gottlieb Steen & Hamilton LLP acted as legal advisor to Takeda Pharmaceutical Company Limited. Evercore Partners acted as financial advisor to Takeda Pharmaceutical Company Limited. Takeda will host a media/investors conference call at 7:30 p.m. EST January 9, 2017 (9:30 a.m. JST January 10, 2017) to discuss the transaction. You can listen to the conference call at the following link:http://www.Takeda.com/investor-information/results/. A replay of the conference call will be available within 24 hours. In light of this announcement, ARIAD will not be presenting today at the 35th Annual J.P. Morgan Healthcare Conference. About ARIAD Pharmaceuticals ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm). About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.Takeda.com/news. Additional information about Takeda is available through its corporate website, www.Takeda.com. Additional Information The tender offer described in this press release has not yet commenced. This press release is provided for informational purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any securities. At the time the tender offer is commenced, Takeda and Merger Sub intend to file with the Securities and Exchange Commission (the “SEC”) a Tender Offer Statement on Schedule TO containing an offer to purchase, a form of letter of transmittal and other documents relating to the tender offer, and ARIAD intends to file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Takeda, Merger Sub and ARIAD intend to mail these documents to ARIAD’s stockholders. Investors and stockholders should read those filings carefully when they become available as they will contain important information about the tender offer. Those documents may be obtained without charge at the SEC’s website at www.sec.gov. The offer to purchase and related materials may also be obtained (when available) for free by contacting the information agent for the tender offer. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking information related to Takeda, ARIAD and the proposed acquisition of ARIAD by Takeda that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Forward-looking statements in this document include, among other things, statements about the potential benefits of the proposed acquisition, anticipated earnings accretion and growth rates, Takeda’s and ARIAD’s plans, objectives, expectations and intentions, the financial condition, results of operations and business of Takeda and ARIAD, ARIAD’s products, ARIAD’s pipeline assets and development, the acceleration of the development of cancer treatments; the expected timing of brigatinib approval in the U.S., and the anticipated timing of closing of the acquisition. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of ARIAD’s stockholders will tender their shares in the tender offer and the possibility that the acquisition does not close; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Takeda’s common stock and on Takeda’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to sustain and increase the rate of growth in revenues for ARIAD’s products despite increasing competitive, reimbursement and economic challenges; whether and when any drug applications may be filed in any jurisdictions for any indications or any additional indications for ARIAD’s products or for ARIAD’s pipeline assets; whether and when the FDA or any other applicable regulatory authorities may approve any such applications, which will depend on its assessment of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by the FDA or other regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of ARIAD’s products and ARIAD’s pipeline assets; and competitive developments. Other factors that may cause actual results to differ materially include those set forth in the reports that ARIAD files from time to time with the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2015 and quarterly and current reports on Form 10-Q and 8-K, as well as the Tender Offer Statement on Schedule TO and other tender offer documents filed by Merger Sub and Parent. Many of these factors are beyond ARIAD’s control. Unless otherwise required by applicable law, ARIAD disclaims any intention or obligation to update forward-looking statements contained in these documents as the result of new information or future events or developments.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), a rare cancer-focused innovative biotechnology company, today announced a conference call and webcast to discuss the clinical data presented on brigatinib, the Company’s investigational anaplastic lymphoma kinase (ALK) inhibitor, at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC). Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer of ARIAD will host the call. Dr. Clackson will be joined by Karen Reckamp, MD, associate professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Lung Cancer and Thoracic Oncology Program at City of Hope Comprehensive Cancer Center (COHCCC). The call will be held Wednesday, December 7, 4:00 p.m. Central European Time (10:00 a.m. Eastern Time). The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com. The call can be accessed by dialing 844-249-9386 (domestic) or 270-823-1534 (international) five minutes prior to the start time and providing the pass code 20888507. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks. About ARIAD ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).